DGAP-News: New Business Segment: Treatment of Fibroadenoma - UMS AG Signs Agreement with IceCure
(firmenpresse) - DGAP-News: UMS United Medical Systems International AG / Key word(s):
Alliance
New Business Segment: Treatment of Fibroadenoma - UMS AG Signs
Agreement with IceCure
18.05.2011 / 09:54
---------------------------------------------------------------------
New Business Segment: Treatment of Fibroadenoma - UMS AG Signs Agreement
with IceCure
Hamburg, May 18, 2011 - UMS United Medical Systems International AG (UMS/
ISIN DE0005493654) has entered into an exclusive agreement in the United
States with IceCure Medical, an innovative provider of medical technology
from Israel, for the mobile deployment of IceCure's medical product
IceSense3 for cryoablation. IceSense3 is approved by the Food and Drug
Administration (FDA) in the United States for the treatment of benign
tumors in the female breast (fibroadenoma).
The partnership with IceCure adds an additional treatment field to UMS's
breast care segment. Cryoablation or cryotherapy is a non-invasive
procedure to remove benign tumors in the female breast. In the United
States alone around 500,000 of these tumors are surgically removed every
year.
UMS plans to build up the U.S. market for mobile services using IceSense3
in the next six to twelve months. By offering daily mobile cryoablation
systems in combination with modern ultrasound technology, UMS is expanding
its services to physicians to include another full-service package on
attractive conditions.
About UMS AG
UMS International AG is a provider of innovative healthcare delivery
concepts in the growth segment of high-tech medicine. UMS pioneered the
mobile deployment of high-class medical systems and markets a comprehensive
range of full-service solutions for hospitals and specialists. The
forward-looking concepts include complete services for the customer,
covering everything from system management to the provision of trained
application specialists. The UMS Group currently has around 200 employees
worldwide and serves over 600 customers.
Contact
Wiebke Budwasch, Tel: (040) 50 01 77-00, Fax: (040) 50 01 77-77, E-Mail:
investor(at)umsag.com
End of Corporate News
---------------------------------------------------------------------
18.05.2011 Dissemination of a Corporate News, transmitted by DGAP - a
company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: UMS United Medical Systems International AG
Borsteler Chaussee 53
22453 Hamburg
Deutschland
Phone: +49 (0)40 - 500 177 - 00
Fax: +49 (0)40 - 500 177 - 77
E-mail: investor(at)umsag.com
Internet: www.umsag.com
ISIN: DE0005493654
WKN: 549365
Listed: Regulierter Markt in Frankfurt (Prime Standard);
Freiverkehr in Berlin, Düsseldorf, Hamburg, München,
Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------
125083 18.05.2011
Datum: 18.05.2011 - 09:54 Uhr
Sprache: Deutsch
News-ID 34132
Anzahl Zeichen: 0
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 272 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: New Business Segment: Treatment of Fibroadenoma - UMS AG Signs Agreement with IceCure"
steht unter der journalistisch-redaktionellen Verantwortung von
UMS United Medical Systems International AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
